Independent report · Healthcare

Orange Health Labs: US$30m Series C

November 7, 2026 · By Reena

An Orange Health Labs phlebotomist with a patient Source: Orange Health Labs website

An Orange Health Labs phlebotomist with a patient Source: Orange Health Labs website

Independent report content

ROUNDSeries C · US$30m (₹277 crore) · reported May–June 2026
LEADIron Pillar (about ₹156 crore)
EXISTING INVESTORSBertelsmann, Accel India, General Catalyst
NEW INVESTORSCrescent Enterprises, Good Capital, Paramark Frontier Fund
FILING4,579,270 Series C CCPS at ₹604.72 each
EARLIER FUNDINGNearly US$50m: Series B US$25m (2022, General Catalyst, Bertelsmann); US$12m (2024, Amazon Sambhav Venture Fund)
REVENUEFY24 ₹49.4 crore · FY25 ₹84–88 crore · FY26 ₹138.6 crore (+65%)
LOSSFY25 net loss ₹81.2 crore · FY26 loss before tax ₹97 crore
THE ACCESS POINT Orange Health is private. The Series C was taken by funds. Individuals can reach it only through those funds or rare secondaries.

Executive decision summary

THE BOTTOM LINE Orange Health Labs sends a phlebotomist to your home and promises blood-test results the same day, from its own labs. Revenue rose 65% to ₹138.6 crore in FY26 and the Series C of US$30m gives it room to expand. It still spent about ₹1.73 for every ₹1 earned, and loss before tax widened to ₹97 crore. Diagnostics is a business of density and volume: it works when each collector and lab handles many tests a day.
WHICH INVESTOR Fits you IF you want exposure to Indian consumer diagnostics growing faster than the chains and can accept losses for several years. Look elsewhere IF you want profitable diagnostics now; Dr Lal PathLabs, Metropolis and Thyrocare are listed and profitable.
COMFORT FIT Orange Health = a home-delivery service for blood tests. Dr Lal PathLabs, Metropolis, Thyrocare = the listed diagnostics chains. Healthians, Redcliffe, Tata 1mg Labs = other home-collection rivals.
THE RUPEIA NUMBER ₹1.73 spent per ₹1 earned in FY26, on revenue of ₹138.6 crore.

1 CLAIM REGISTER: EVIDENCE GRADING

A = government or regulator record. B = statutory filing. C = independent press. D = company announcement.

ClaimSourceGradeRupeia assessment
US$30m Series C led by Iron PillarDealroom; Venture Intelligence; StartupResearcherCEstablished; date reported as May or June 2026.
4,579,270 CCPS at ₹604.72 = ₹277 croreRegulatory filings as reportedB/CEstablished.
FY26 revenue ₹138.6 crore; loss before tax ₹97 croreAscendants; Indian RetailerB/CEstablished.
FY25 revenue ₹84–88 croreInc42; Indian RetailerCOutlets differ.

2 COMPANY OVERVIEW & FOUNDING STORY

Orange Health Labs is a Bengaluru diagnostics company that offers fast, at-home blood tests in a market where most samples are collected at labs. A trained phlebotomist arrives, usually within a short slot, and results come the same day. It runs its own labs and has added collection centres in some cities.

3 TIMELINE

DateEvent
2022US$25m Series B
2024US$12m round led by Amazon Sambhav Venture Fund
FY25Revenue about ₹87.7 crore
FY26Revenue ₹138.6 crore
May–Jun 2026US$30m Series C led by Iron Pillar

4 FUNDING HISTORY & INVESTOR BEHAVIOUR

DateRoundAmountInvestors
2022Series BUS$25mGeneral Catalyst, Bertelsmann
2024RoundUS$12mAmazon Sambhav Venture Fund
2026Series CUS$30m (₹277 crore)Iron Pillar (lead, ~₹156 crore); Bertelsmann, Accel, General Catalyst; Crescent, Good Capital, Paramark

Total capital raised is now about US$80m. Insiders all returned, which helps credibility.

RUPEIA CALCULATION ₹277 crore from 4,579,270 shares at ₹604.72. Iron Pillar's about ₹156 crore is 56% of the round. The company has not published a valuation.

5 FINANCIAL FORENSICS

MetricFY24FY25FY26
Revenue₹49.4 crore₹84–88 crore₹138.6 crore
Growth+77%+65%
Loss before taxn/a₹87.4 crore₹97 crore
Loss % of revenuen/a~100%70%

Loss as a share of revenue fell from about 100% to 70% in a year, a solid improvement. In absolute terms the loss grew 11%.

6 BUSINESS MODEL & UNIT ECONOMICS

LineHow it earnsPressure point
Home collection testsFee per test packageCollector utilisation; cost per visit
Lab processingOwn labs process samplesLab throughput
Collection centres and B2BWalk-ins and partnersCapex
Health packages and subscriptionsBundled testsRepeat rates

The key metric is revenue per collector per day. If a collector does more visits per slot, margins improve quickly.

7 MARKET & COMPETITIVE ANALYSIS

PeerStatusPosition
Dr Lal PathLabsListedLargest chain; profitable
MetropolisListedChain with B2B focus
ThyrocareListedPan-India low-price tests
Healthians, Redcliffe Labs, Tata 1mg LabsPrivateHome-collection rivals
Apollo DiagnosticsListed parentHospital-linked chain

8 VALUATION ANALYSIS

BasisFigure
Published valuationNone
₹277 crore at 15–20% stake₹1,385–1,850 crore post-money (illustration)
Multiple of FY26 revenue10–13x

Rupeia arithmetic only. Listed chains trade on profits, so any private price for Orange is a bet on scale.

9 SCENARIO ANALYSIS

ScenarioProbabilityWhat happens
Bull25%Revenue passes ₹250 crore by FY28 with breakeven in sight
Base50%Revenue grows 40–50%; losses narrow slowly
Bear25%Competition from chains and Tata 1mg slows growth

10 RISK ANALYSIS: RED FLAG LEDGER & KILL CONDITIONS

RiskSeverityKill condition
LossesHighFY27 loss above ₹100 crore
Competition and price cutsHighPackages discounted by rivals
Quality and accreditationMediumA NABL or sample-handling incident
Unit economicsMediumCost per visit not falling

11 INVESTOR CLASS ANALYSIS

HNIs and family offices

Access to Orange Health Labs is through its funds, a negotiated co-investment or the unlisted market where one exists. Price any offer against the latest round or filing.

Institutions

Strategic and institutional investors set the price; follow their disclosures.

NRIs

NRIs can hold unlisted Indian shares under FEMA pricing and reporting rules; repatriation depends on the account route used.

12 THE EARLY SIGNAL: EVENTS TO WATCH

WhenEvent
2027FY26 accounts and Series C valuation filings
2027New cities and labs
2027–28Breakeven target

13 RUPEIA FINAL INDEPENDENT VIEW

Orange Health is growing faster than the chains and has narrowed its loss ratio. It still burns cash in a business that listed peers run at 20% margins.

THE RUPEIA NUMBER ₹1.73 spent per ₹1 earned in FY26, on revenue of ₹138.6 crore.
RUPEIA VERDICT A good consumer diagnostics name with a long path to profit. Suitable for growth-fund style capital.

Frequently asked questions

How much did Orange Health Labs raise?

US$30m (₹277 crore) in a Series C led by Iron Pillar in 2026.

What is its revenue?

₹138.6 crore in FY26, up 65%.

Is it profitable?

No. Loss before tax was ₹97 crore in FY26.

What does it do?

At-home blood tests with same-day results.

Source log

Dealroom: Orange Health Labs US$30m Series C

Venture Intelligence: Orange Health US$30m

Ascendants: Orange Health FY26

Indian Retailer: Orange Health FY26

Inc42: Orange Health financials

StartupResearcher: Orange Health Series C

DISCLAIMER This report is independent research by Rupeia Investments Co. built only from public sources as of the date shown. It is not an offer, solicitation or investment advice, and it is not a recommendation to buy or sell any security. Private-company figures are drawn from filings and media reports and may be revised. Unlisted and private-market investments are illiquid and carry a risk of total loss. Investors should take independent advice.